Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
BMC Health Serv Res ; 18(1): 626, 2018 08 09.
Article in English | MEDLINE | ID: mdl-30092801

ABSTRACT

BACKGROUND: The Australian Government Department of Veterans' Affairs (DVA) Veterans' Medicines Advice and Therapeutics Education Services (Veterans' MATES) programme conducted two intervention (March 2009, follow-up intervention June 2012) both of which aimed to reduce hypnotic use among Australian veterans. We evaluated the effectiveness of the interventions, and estimated the associated health consequences. METHODS: Both interventions targeted veterans who had been dispensed hypnotics prior to the intervention. Patient-specific prescriber feedback containing patient details and the volume of hypnotics dispensed, along with tailored educational information, was mailed to general practitioners. Veterans, pharmacists and directors of care in residential aged care facilities were mailed tailored educational information. Interrupted time-series and segmented regression modelling were used to determine the effect of the two interventions on the rate of hypnotics dispensing. The cumulative patient-months of hypnotic treatment avoided as a result of the interventions was calculated. We estimated improvements in health consequences of as a result of hypnotic treatment avoided based on the results of cohort studies in the same population identifying the association between hypnotic and sedative use on the outcomes of falls, and confusion. RESULTS: After the first Veterans' MATES intervention in March 2009, hypnotic use declined by 0.2% each month, when compared to the baseline level (p = 0.006). The intervention effect was attenuated after one year, and use of hypnotics was found to increase by 0.2% per month after March 2010. Following the second intervention in June 2012, there was a further significant decline in use of 0.18% each month over the 12 months of follow up (p = 0.049). The cumulative effect of both interventions resulted in 20,850 fewer patient-months of treatment with hypnotics. This cumulative reduction in hypnotic use was estimated to lead to a minimum of 1 fewer hospital admissions for acute confusion and 7 fewer hospital admissions due to falls. CONCLUSIONS: The Veterans' MATES insomnia interventions which involved multiple stakeholders were effective in reducing hypnotic use among older Australians. Repetition of key messages led to sustained practice change.


Subject(s)
Health Personnel/education , Hypnotics and Sedatives/therapeutic use , Patient Education as Topic , Sleep Initiation and Maintenance Disorders/drug therapy , Veterans , Accidental Falls/statistics & numerical data , Australia , General Practitioners , Health Facility Administrators , Homes for the Aged , Hospitalization/statistics & numerical data , Humans , Hypnotics and Sedatives/adverse effects , Interrupted Time Series Analysis , Pharmacists
2.
Aust Fam Physician ; 41(1-2): 45-9, 2012.
Article in English | MEDLINE | ID: mdl-22276284

ABSTRACT

BACKGROUND: Older people with dementia may be particularly susceptible to cognitive impairment associated with anticholinergic and sedative medicines. This impairment may be misattributed to the disease process itself. OBJECTIVE: This review examines clinical considerations associated with using anticholinergic and sedative medicines in people with dementia or incipient cognitive impairment. It highlights issues associated with concomitant use of cholinesterase inhibitors and anticholinergic medicines, and pharmacotherapy of conditions that commonly occur in people with dementia. DISCUSSION: Use of medicines with anticholinergic or sedative properties may result in adverse events by increasing the overall anticholinergic or sedative load. Patients may benefit from clinicians reviewing the anticholinergic load of the current medicine regimen before the initiation of cholinesterase inhibitors or memantine. Reducing the number and dose of anticholinergic and sedative medicines may improve cognitive function and reduce the likelihood of adverse events.


Subject(s)
Cholinergic Antagonists/adverse effects , Cholinesterase Inhibitors/adverse effects , Cognition Disorders/chemically induced , Dementia/metabolism , Hypnotics and Sedatives/adverse effects , Antidepressive Agents/adverse effects , Antipsychotic Agents/adverse effects , Histamine Antagonists/adverse effects , Humans
SELECTION OF CITATIONS
SEARCH DETAIL